Plaque Rupture and Thrombosis
Davide Capodanno, Full Professor of Cardiology at the University of Catania, shared on X:
“Plaque rupture with thrombosis drives ACS, and thin-cap fibroatheroma is the archetypal high-risk plaque. There are consistent features of vulnerability across imaging modalities (large plaque burden, small MLA, TCFA, high LCBI, positive remodelling, etc.), with risk increasing when multiple features coexist. Yet absolute event rates remain low, consistent with pathology data showing most plaque ruptures are clinically silent.
So should we prophylactically stent high-risk plaques? According to this Viewpoint, completed trials (PROSPECT ABSORB, PREVENT) suggest no durable reduction in death or MI versus optimal medical therapy—benefits are limited to fewer revascularisations, at the cost of many unnecessary PCIs. With modern medical therapy, a wait-and-see strategy appears safe, avoiding most interventions without adverse consequences. For now, data favor surveillance and aggressive medical therapy over preventive PCI.
READ THE VIEWPOINT HERE.
Stay updated with Hemostasis Today.
-
Jun 15, 2026, 10:49Aurelio Maggio: How Is The Treatment Landscape Of Thrombotic Thrombocytopenic Purpura Evolving?
-
Jun 15, 2026, 10:49Marek Mráz: A Landmark EHA 2026 for Our Lab
-
Jun 15, 2026, 10:32Magnus Ek: Operational Excellence in Delivering Seamless Access for 17,000 Delegates at EHA 2026 Congress
-
Jun 15, 2026, 10:15Carol Bewick: Why the Global Community Makes EHA 2026 Unforgettable
-
Jun 15, 2026, 10:07Habib Bennaceur: Driving Haemoglobinopathies Progress Across Multiple Clinical Programmes At EHA 2026
-
Jun 14, 2026, 22:49Cihan Ay: From First Oral Presentation to Pro and Con Debate – A 20-Year EHA Journey
-
Jun 14, 2026, 19:54Tareq Abadl: What Happens If You Transfuse the Wrong Blood Group?
-
Jun 14, 2026, 19:46Amber Yates: Stretching Scientific Muscles in Areas of Hematology – Day 2 at EHA 2026
-
Jun 14, 2026, 19:41Peter Loffelhardt: Thousands of People Coming in – Second Day at EHA 2026